Fredrik I Thege
Overview
Explore the profile of Fredrik I Thege including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sans M, Chen Y, Thege F, Dou R, Min J, Yip-Schneider M, et al.
bioRxiv
. 2023 Aug;
PMID: 37645752
Background: The development of diverse spatial profiling technologies has provided an unprecedented insight into molecular mechanisms driving cancer pathogenesis. Here, we conducted the first integrated cross-species assessment of spatial transcriptomics...
2.
Sans M, Makino Y, Min J, Rajapakshe K, Yip-Schneider M, Schmidt C, et al.
Cancer Discov
. 2023 Jun;
13(8):1844-1861.
PMID: 37285225
Significance: Identification of the molecular features driving IPMN development and differentiation is critical to prevent cancer progression and enhance risk stratification. We used spatial profiling to characterize the epithelium and...
3.
Rupani D, Thege F, Chandra V, Rajaei H, Cowan R, Wormann S, et al.
Development
. 2022 Dec;
150(2).
PMID: 36458554
Adenosine deaminase acting on RNA 1 (ADAR1) is an RNA-binding protein that deaminates adenosine (A) to inosine (I). A-to-I editing alters post-transcriptional RNA processing, making ADAR1 a crucial regulator of...
4.
Thege F, Rupani D, Barathi B, Manning S, Maitra A, Rhim A, et al.
Cancer Res
. 2022 Jun;
82(15):2761-2776.
PMID: 35666804
Significance: A streamlined platform for programmable CRISPR gene activation enables rapid evaluation and functional validation of putative oncogenes in vivo.
5.
Thege F, Cardle I, Gruber C, Siemann M, Cong S, Wittmann K, et al.
PLoS One
. 2022 May;
17(5):e0267882.
PMID: 35617275
Tumors display rich cellular heterogeneity and typically consist of multiple co-existing clones with distinct genotypic and phenotypic characteristics. The acquisition of resistance to chemotherapy has been shown to contribute to...
6.
Wormann S, Zhang A, Thege F, Cowan R, Rupani D, Wang R, et al.
Nat Cancer
. 2022 Feb;
2(12):1338-1356.
PMID: 35121902
Despite efforts in understanding its underlying mechanisms, the etiology of chromosomal instability (CIN) remains unclear for many tumor types. Here, we identify CIN initiation as a previously undescribed function for...
7.
Thege F, Gruber C, Cardle I, Cong S, Lannin T, Kirby B
Anal Biochem
. 2019 Feb;
577:26-33.
PMID: 30790546
Capture and analysis of circulating tumor cells (CTCs) holds promise for diagnosing and guiding treatment of pancreatic cancer. To accurately monitor disease progression, capture platforms must be robust to processes...
8.
Lannin T, Thege F, Kirby B
Cytometry A
. 2016 Oct;
89(10):922-931.
PMID: 27754580
Advances in rare cell capture technology have made possible the interrogation of circulating tumor cells (CTCs) captured from whole patient blood. However, locating captured cells in the device by manual...
9.
Thege F, Lannin T, Saha T, Tsai S, Kochman M, Hollingsworth M, et al.
Lab Chip
. 2014 Apr;
14(10):1775-84.
PMID: 24681997
We have developed and optimized a microfluidic device platform for the capture and analysis of circulating pancreatic cells (CPCs) and pancreatic circulating tumor cells (CTCs). Our platform uses parallel anti-EpCAM...
10.
Rhim A, Thege F, Santana S, Lannin T, Saha T, Tsai S, et al.
Gastroenterology
. 2013 Dec;
146(3):647-51.
PMID: 24333829
Hematogenous dissemination is thought to be a late event in cancer progression. We recently showed in a genetic model of pancreatic ductal adenocarcinoma that pancreas cells can be detected in...